Werewolf Therapeutics Inc.

HOWL | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.99

+$0.01 (+1.02%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.02%

(1D)

Rating

Updated: Sep 5, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $48.03M

1D Range

0.97 1.00

52W Range

0.27 2.38

Valuation (TTM)

PE -1.34

PB 2.92

EV/EBITDA -1.16

Valuation (NTM)

Forward PE N/A

Forward PEG 0.04

Price Target $6.50

Cash Flow

FCF Yield -63.3%

SBC Adj. FCF Yield -71.3%

SBC Impact -12.6%

Margins

Gross Margin 86.4%

Operating Margin -121.8%

FCF Margin -143.6%

Growth (CAGR)

Revenue 3Y | 5Y -5.4% | 7.5%

Dil EPS 3Y | 5Y 25.0% | 18.2%

FCF 3Y | 5Y 13.2% | 2.3%

Returns

ROA -143.3%

ROE -167.0%

ROIC -157.0%

Financial Health

Net Cash

$21.99M

Current Ratio 2.91

Interest Coverage -5.62

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the...

Sector Healthcare

Industry Biotechnology

Employees 39

IPO Date Apr 29, 2021

Website werewolftx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 3, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$6.50

Upside

+556.57%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞